-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Yingpai Pharmaceutical-B (07630.HK) announced that the latest clinical data from the three major pipeline projects (namely Senapali (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted and displayed on a poster at the 2026 European Society of Medical Oncology (ESMO) conference. Accepted data include: (i) recent progression-free survival (PFS) data from the phase III FLAMES study of senapalil as a first-line maintenance treatment for advanced ovarian cancer; (ii) recent data from multiple cohorts of the ongoing phase I/II study of IMP1734, covering monotherapy, combined treatment with paclitaxel for advanced solid tumors, and abiraterone for metastatic prostate cancer; and (iii) IMP1707 (a selective PARP1 inhibitor that penetrates the central nervous system) in patients with advanced solid tumors with HRR mutations /Preliminary results from the Phase II study.

Zhitongcaijing·07/19/2026 23:41:06
Listen to the news
Zhitong Finance App News, Yingpai Pharmaceutical-B (07630.HK) announced that the latest clinical data from the three major pipeline projects (namely Senapali (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted and displayed on a poster at the 2026 European Society of Medical Oncology (ESMO) conference. Accepted data include: (i) recent progression-free survival (PFS) data from the phase III FLAMES study of senapalil as a first-line maintenance treatment for advanced ovarian cancer; (ii) recent data from multiple cohorts of the ongoing phase I/II study of IMP1734, covering monotherapy, combined treatment with paclitaxel for advanced solid tumors, and abiraterone for metastatic prostate cancer; and (iii) IMP1707 (a selective PARP1 inhibitor that penetrates the central nervous system) in patients with advanced solid tumors with HRR mutations /Preliminary results from the Phase II study.